NEWS
LATEST
FULL LIST
-
Prellis Biologics and Eli Lilly Sign Multi-Target Antibody Discovery Agreement
Prellis Biologics has entered into a multi-target drug discovery and development collaboration with Eli Lilly and Company. The agreement combines Prellis’ organoid-based antibody discovery technology with Lilly’s research and commercialization capabilities to develop next-generation human antibody therapeutics. Financial terms were not disclosed, though Prellis stated it will receive an upfront payment, potential development and sales…
-
Humacyte Reports Positive Data on Bioengineered Vessels for Vascular Repair and Coronary Bypass
Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company focused on creating universally implantable bioengineered human tissues, recently announced two notable scientific publications highlighting the potential of its acellular tissue–engineered vessel (ATEV™) platform in both clinical and preclinical settings. Together, these updates underscore Humacyte’s progress in advancing biofabricated vascular grafts from trauma care into cardiovascular surgery. Symvess…
-
eGenesis Wins FDA Green Light for Gene-Edited Pig Kidney Trial
Massachusetts-based biotech eGenesis has received a key FDA clearance to launch a landmark clinical trial testing EGEN-2784, a multiplex gene-edited pig kidney designed for human transplantation. The investigational new drug (IND) approval enables a combined Phase 1/2/3 study that will evaluate the organ’s safety and performance in patients with end-stage kidney disease (ESKD) over a…
-
Terumo Acquires OrganOx for $1.5 Billion: A Landmark Deal in Organ Preservation and Transplantation
Terumo Corporation has announced a $1.5 billion acquisition of OrganOx Limited, a University of Oxford spin-out and global leader in organ preservation devices. The move marks Terumo’s formal entry into the organ transplantation space, an area of growing medical and commercial importance as healthcare systems worldwide grapple with organ shortages and increasing transplantation demand. OrganOx’s…
-
TISSIUM’s COAPTIUM Connect ushers in photopolymer 3‑D printing for implantables
The FDA’s recent De Novo authorization of COAPTIUM Connect removes a long‑standing barrier for photopolymer 3‑D‑printed implants. Developed by Paris‑ and Cambridge‑based TISSIUM and produced on a bespoke printing line co‑engineered with 3D Systems, the fully bioabsorbable sleeve offers an atraumatic, suture‑free method for coupling severed peripheral nerves. U.S. commercial launch began on 23 July 2025, marking the first…
-
Xeltis Reports Positive 24-Month Clinical Success for Regenerative CABG Conduit
Xeltis, a medtech innovator headquartered in The Netherlands, continues to advance the frontier of regenerative cardiovascular implants with new clinical data supporting its Xabg coronary artery bypass conduit. The company announced encouraging results from a European feasibility study, showing both positive safety and patency outcomes in patients undergoing CABG surgery. This builds upon a prior…
-
Aspect Biosystems Showcases Bioprinted Adrenal Tissue Data at ENDO 2025
At the 2025 annual meeting of the Endocrine Society (ENDO) in San Francisco, Aspect Biosystems unveiled compelling preclinical data demonstrating the therapeutic potential of its adrenal Bioprinted Tissue Therapeutics (BTTs) a novel cell therapy approach aimed at restoring hormone function in patients with primary adrenal insufficiency (PAI). The data, presented through both oral and poster…
-
CollPlant Expands U.S. Footprint with Strategic Hire to Lead Commercial GrowthBusiness of Biofabrication
CollPlant Biotechnologies (NASDAQ: CLGN), a leader in recombinant human collagen (rhCollagen) innovation, has appointed Bowman Bagley as Vice President, Commercial North America. The newly created position underscores CollPlant’s growing commitment to scaling its regenerative medicine and bioprinting platforms across the U.S. and Canadian markets. Leadership with Deep Roots in Biomaterials Bagley, an experienced executive in…
-
Nanochon Receives Green Light from Health Canada for First-in-Human Trial of 3D-Printed Chondrograft™ Implant
Washington D.C. based startup Nanochon has announced a major regulatory milestone: Health Canada has approved the company’s trial design, granting permission to begin its first-in-human clinical study for the company’s patented Chondrograft™ System, a biofabricated cartilage restoration implant. The upcoming early feasibility study will enroll 10 patients between the ages of 22 and 60 who…
-
Boston Based Linton Lifesciences Launches – Biofabricated Vascular Grafts
Boston-based Linton Lifesciences launches this week with a patient-first mission: replace today’s underperforming vascular grafts with bioprinted grafts that help people “do more of what they love.” By combining advanced chemistry, robotics, and 3D bioprinting, the company aims to build grafts that give dialysis and vascular-disease patients extra years of quality life and time they…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 